Based on ratings from 14 stock analysts, the Incyte Corp stock price is expected to increase by 25.69% in 12 months. This is calculated by using the average 12-month stock price forecast for Incyte Corp. The lowest target is $58.00 and the highest is $92.00. Please note analyst price targets are not guaranteed and could be missed completely.
Incyte Corp has a total of 14 Wall St Analyst ratings. There are 5 buy ratings, 9 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Incyte Corp will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
reni benjamin JMP Securities | Hold | None | downgraded | Feb 14, 2024 |
evan seigerman BMO Capital | Hold | $64.0 | maintained | Feb 14, 2024 |
stephen willey Stifel Nicolaus | Hold | $68.0 | maintained | Feb 14, 2024 |
andrew berens Leerink Partners | Buy | $83.0 | maintained | Feb 13, 2024 |
brian abrahams RBC Capital | Hold | $65.0 | maintained | Feb 13, 2024 |
derek archila Wells Fargo | Hold | $61.0 | rated | Feb 13, 2024 |
tazeen ahmad Bank of America Securities | Hold | $69.0 | reiterated | Feb 13, 2024 |
salveen richter Goldman Sachs | Hold | $63.0 | maintained | Feb 13, 2024 |
david lebovitz Citi | Buy | $81.0 | maintained | Feb 13, 2024 |
salim syed Mizuho Securities | Hold | $77.0 | initiatedcoverage | Feb 9, 2024 |
mara goldstein Mizuho Securities | Hold | $77.0 | rated | Feb 5, 2024 |
allison bratzel Piper Sandler | Buy | $85.0 | maintained | Jan 18, 2024 |
jessica fye J.P. Morgan | Hold | $58.0 | maintained | Jan 4, 2024 |
jay olson Oppenheimer | Buy | $92.0 | maintained | Dec 12, 2023 |
michael schmidt Guggenheim | Buy | None | upgraded | Dec 4, 2023 |
srikripa devarakonda Truist Financial | Buy | $91.0 | maintained | Nov 28, 2023 |
marc frahm TD Cowen | Buy | $92.0 | maintained | Oct 31, 2023 |
vikram purohit Morgan Stanley | Hold | $74.0 | maintained | May 3, 2023 |
maneka mirchandaney Evercore ISI | Hold | $80.0 | maintained | May 2, 2023 |
jasper hellweg Argus Research | Buy | $90.0 | maintained | Feb 27, 2023 |
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; and in-license agreements with Agenus, Merus, MacroGenics, and Syndax. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
When did it IPO
0
Staff Count
2,524
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Herve Hoppenot
Market Cap
$13.01B
In 2023, INCY generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that INCY's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
NBIX-USD
$132.31
PODD-USD
$191.01
LKQ-USD
$50.04
JKHY-USD
$173.1
LNT-USD
$48.35
FOXA-USD
$29.95